Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11952434 Immunomodulators

Patent 11952434 was granted and assigned to Bristol-Myers Squibb Company on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Bristol-Myers Squibb Company

0

Current Assignee

Bristol-Myers Squibb Company

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Claudio Mapelli0

Kevin W. Gillman0

David R. Langley0

Nicholas A. Meanwell0

Paul Michael Scola0

Michael A. Poss0

Yunhui Zhang0

Jason Goodrich0

...

Date of Patent

April 9, 2024

0

Patent Application Number

177253400

Date Filed

April 20, 2022

0

Patent Citations

US Patent 9850283 Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

0

US Patent 9856292 Immunomodulators

0

US Patent 9861680 Immunomodulators

0

US Patent 9879046 Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

0

US Patent 9944678 Immunomodulators

0

US Patent 10143746 Immunomodulators

0

US Patent 10358463 Immunomodulators

0

US Patent 10406251 PD-L1 binding polypeptides for imaging

0

...

Patent Primary Examiner

Christina Bradley

0

Patent abstract

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11952434 Immunomodulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool